Plays important roles in regulating apoptosis, metabolism and mitochondrial dynamics (PubMed:30510213, PubMed:26876167, PubMed:26219591, PubMed:20436477). MTCH2 acts as a receptor for the truncated form of pro-apoptotic BH3-interacting domain death agonist (p15 BID) and has therefore a critical function in apoptosis (PubMed:20436477). Plays a critical role in controlling the quiescence/cycling of hematopoietic stem cells (HSCs) (PubMed:20436477, PubMed:26876167, PubMed:26219591). Acts as a regulator of mitochondrial fusion, essential for the naive-to-primed interconversion of embryonic stem cells (ESCs) (PubMed:30510213). Acts as a regulator of lipid homeostasis and has a regulatory role in adipocyte differentiation and biology (PubMed:28127879, PubMed:26876167). Interacts with p15BID. Expressed in a wide variety of tissues. Predominant expressed in liver, kidney, heart, skeletal muscle and testis. Mice homozygous for a knockout allele exhibit abnormal mesoderm development, disorganized extraembryonic tissue, lack of amnion and chorion formation, decreased embryo size and lethality at around 7.5 dpc (PubMed:20436477). Conditional knockout in the liver decreases the sensitivity of mice to Fas-induced hepatocellular apoptosis and prevents the recruitment of tBID to liver mitochondria (PubMed:20436477). Conditional knockout in skeletal muscle results in increased mitochondrial mass and metabolism granting protection against diet-induced obesity (PubMed:26876167). Belongs to the mitochondrial carrier (TC 2.A.29) family.